| Detailed information |
|---|
| CancerLivER ID | 2282 |
| Biomarker | Stathmin |
| Biomarker Name/Symbol (given in Publication) | Stathmin |
| Biomolecule | Protein |
| Subject | Human |
| Degree of Validity | Significantly associated with early intrahepatic recurrence of HCC and validated on independent dataset |
| Experimental Condition | Early recurrence v/s No recurrence HCC |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Downregulated in recurrence HCC than non-recurrence HCC (with fold change 0.56) |
| Level of significance | p < 0.05 |
| Source | Tissue |
| PMID | 17391314 |
| Type of Biomarker | Prognostic |
| Pathway | Signal transduction |
| Cohort | Training dataset: 12 early recurrence and 15 no recurrence patients; validation dataset :6 early recurrence and 7 no recurrence patients |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Early recurrence v/s No recurrence HCC |
| Year of Publication | 2007 |
| Clinical trial | YES |
| NCT No# (Clinical trial) | NCT01251458 |